Clinical efficacy and safety of Roxadustat in the treatment of renal anemia in patients with undergoing maintenance hemodialysis combined with viral hepatitis
CHEN Li
ZHANG Wen-yu
CHANG Wen-xiu
Abstract：Objective To explore the clinical efficacy and safety of hypoxic inducible factor prolyl hydroxylase inhibitors—Roxadustatin patients with viral hepatitis undergoing maintenance hemodialysis and renal anemia.Methods 30 patients with viral hepatitis undergoing maintenance hemodialysis,renal anemia and poor therapeutic effect of erythropoietin from the Blood Purification Center of Tianjin First Central Hospital from January to December in 2022 were selected and treated withRoxadustatfor 12months.The changes of anemia compliance rate,anemia index,iron metabolism index and related physicochemical index before and after adjustedmedication were compared.Results After 12 months of treatment with Roxadustat,the total hemoglobin compliance rate was 93.3％.The anemia related indicators of patients after treatment include hemoglobin[109.50(102.25,115.00)g/L vs.117.50(113.25,124.75)g/L],Z=4.329,P＜0.001;red blood cell specific volume[(0.30±0.05)％vs.(0.38±0.06)％,t=3.670,P=0.001],and red blood cell count[(3.16±0.60)×1012/L vs.(3.59±0.69)×1012/L,t=5.540,P＜0.001]were increased compared to before treatment,and the difference was statistically significant.The iron metabolism related indicators of patients after treatment include serum iron[9.90(8.32,13.18)]μmol/L vs.13.45(10.80,19.30)μmol/L,Z=3.451,P=0.001],and transferrin saturation[28.35(21.94,33.06)％vs.33.63(26.37,38.95)％,Z=3.211,P=0.001]significantly increased compared to before;ferritin[(274.09±147.51)μg/L vs.(184.44±92.21)μg/L,t=-4.197,P＜0.001],and hepcidin[(120.48±18.61)ng/Lvs.(83.42±16.92)ng/L,t=-3.432,P=0.002]decreased compared to before.After treatment,there was no significant change in systolic blood pressure,diastolic blood pressure,and related physicochemical indicators compared to before treatment(P＞0.05).Conclusion Roxadustat can effectively improve the anemia status of maintenance hemodialysis patients with viral hepatitis with poor treatment effect of erythropoietin,and can also improve the inflammation and iron metabolism of patients with good safety.
Keywords：Roxadustatchronic kidney diseasehypoxic inducible factor prolyl hydroxylase inhibitorsmaintenance hemodialysisviral hepatitisrenal anemia
Publication Date：2024-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 64-67 )